US FDA discloses FY 2016 drug user fee rates
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has published the rates for fiscal year 2016 for user fees the agency intends to collect from makers of prescription drugs, biosimilars and generic drugs and from firms considered pharmacy compounding outsourcing facilities.